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Cancer is one of the major diseases that cause a high number of deaths globally. Of the major 
types of cancers, lung cancer is known to be the most chronic form of cancer in the world. The 
conventional management of lung cancer includes different medical interventions like 
chemotherapy, surgical removal, and radiation therapy. However, this type of approach lacks 
specificity and also harms the adjacent normal cells. Lately, nanotechnology has emerged as a 
promising intervention in the management and treatmn  of lung cancers. Nanotechnology has 
revolutionized the existing modalities and focuses primarily on reducing toxicity and improving 
the bioavailability of anticancer drugs to the target tumor cells. Nanocarrier systems are being 
currently used extensively to exploit and to overcome the obstructions induced by cancers in the 
lungs. The nano-carrier-loaded therapeutic drug delivery methods have shown promising 
potential in treating lung cancer as its target is o control the growth of tumor cells. In this 
review, various modes of nano drug delivery options like liposomes, dendrimers, quantum dots, 
carbon nanotubes and metallic nanoparticles have been discussed. Nano-carrier drug delivery 
systems emerge as a promising approach and thus is expected to provide newer and advanced 
avenues in cancer therapeutics. 
























1. Introduction  
Cancer remains to be one of the major health problems in both developed and developing 
countries globally [1]. Hippocrates first introduced the term “cancer” in 370 BC and stated that 
these are abnormally growing cells due to chromosomal alterations [2]. On an approximate, 
around 1.6 million cancer cases have been reported in the United States alone each year [3]. 
There are more than 100 different types of cancers ategorised by organ and tissues of origin. Of 
all these types, lung cancer is the leading cause of d aths, where, chronic smoking is considered 
to be the major cause, in addition to the other contributing factors. Interestingly, it has been 
reported that men and women are equally exposed to both direct and indirect smoking [4]. About 
1.04 million cases of lung cancer are recorded each year worldwide, with the highest prevalence 
observed in North America and Europe. According to the available statistical data, the 5-year 
relative survival rate for patients having lung caner was a mere 13% in 1975, whereas, during 
1996 to 2003, it increased to 16% [5].  Every year, the number of deaths due to lung cancers is 
far more than the other types of cancers; namely, breast, colorectal or prostate cancer to name a 
few. In developing countries, the percentage of people having lung cancers is exponentially high, 
as more than 50% of cases belong to the local population [6]. Rapid development, urbanization 
and environmental pollution are the other major contributors, apart from smoking habits, that 
account towards the increased number of patients suffering from respiratory diseases [7]. Lung 
cancer is categorised into two categories based on histological assessment, which are; i) Small-
cell lung cancer (SCLC) and ii) Non-small cell lung cancer (NSCLC). [8] In developing 
countries, NSCLC is very common, primarily due to smoking, and it accounts for at least 85% of 
cases of lung cancer, whereas, SCLC accounts for the rest of the 15% cases [9]. NSCLC is 
further categorized into three sub-categories, i.e.a) Adenocarcinoma (AD), b) Large-cell 
carcinoma (LC) and Squamous-cell carcinoma (SQ) [10].  
Inspite boasting of advanced medical interventions like surgical removal, chemotherapy, and 
radiation therapy, nevertheless, it has become evenmore challenging to control the deaths due to 
lung cancer. These traditional approaches lack precision and deliver minimal amounts of 
therapeutic drugs (due to their lipophilic nature and high first-pass metabolism). Due to their 
non-targeting nature, majority of chemotherapeutics a t on normal tissues, leading to adverse 















targeted therapeutic approaches. In recent decades, th  introduction of nanotechnology has 
unlocked new prospects for targeted therapeutic delvery and attributed towards the development 
of nano-based drug delivery systems [12]. These nano-b sed drug delivery systems deliver anti-
cancer drugs in high concentration to the tumor site and prevent the accumulation of such drugs 
in normal organs [13]. A number of databases and search engines like Medline, PubMed, 
HubMed, Clarivate Analytics, Scopus, Science Citation Index (SCI), Indian Citation Index (ICI), 
American Chemical Society (ACS), SciElo, Science Direct etc. were queried out for scientific 
findings and accessing the articles in academic journals, institutional repositories, archives or 
other collection of scientific articles.  This reviw intends to provide an overview and discusses 
the recent advancements in the field of nanocarrier d ug delivery systems for the management of 
lung cancer.   
1.1. Global prevalence of lung cancer 
Over the past few centuries, the prevalence of lungcancer has shifted from being a rare disease 
to a common disease worldwide. Lung cancer is the most commonly occurring cancer in men 
and the third most commonly occurring cancer in women. According to the American Cancer 
Society (ACS), in 2018 alone, it accounted for 234,0 0 newly diagnosed cases, representing 14% 
of all newly diagnosed cancer cases and 154,050 deaths, which is 1.4 folds higher than as seen in 
developed countries [14]. In European countries, there were about 75% death cases among men 
and about 80% of death cases among women which have been reported, due to lung cancer. 
However, the highest mortality among men was recorded in the Central and Eastern Europe 
regions [15], whereas, the highest mortality among women was recorded in the north-western 
parts of Europe, in countries namely, Denmark, UK and Netherlands [16].  
Considering ‘age’ as the detrimental factor for lung cancer, the occurrence of lung cancer before 
44 is very rare for both sexes. A high percentage of mortality has been reported in African, East-
Mediterranean and South-East Asia region in the age group of 45 to 62 years. A similar trend has 
been observed for the middle age group of 54 to 64 years. About 30% of deaths due to lung 
cancer is recorded in the age group of 65 to 74 years from all regions [17]. In comparison to the 
current scenario, it has been predicted that the mortality rate of lung cancer patients may increase 
from 1.6 million to a staggering 3 million. In addition, it has been predicted that the mortality 















has been estimated that more than 50% of lung cancer deaths occur in the Western Pacific region 
followed by the Americas, the European and the South-East Asia regions [3]. 
In contrast, only 1-2% of deaths, due to lung cancer, are recorded from the African and the East-
Mediterranean regions. The Western Pacific region will continue to be ranked 1 in terms of 
mortality due to lung cancer, owing to the high mortality rate [19]. In addition, it is further 
predicted that the gap between other regions will continue to expand. Assessment of the temporal 
trend of lung cancer in countries like Argentina, Cnada, Chile and the US showed two different 
scenarios, i.e., a decrease in the mortality rate among men in both the US and Argentina and an 
increased mortality rate among both men and women in Canada and Chile [18]. A similar 
scenario was observed on the assessment of European countries. The trend of decreasing 
mortality rate of men in countries like Australia and New Zealand is predicted to be continued in 
the future [20]. The similar prediction has been stated for China until 2035 [3]. It has been also 
predicted that in the next two decades; Japan will experience an exponential increase in lung 
cancer cases for both sexes [21]. In developing countries like Egypt, India, Indonesia and Saudi 
Arabia, it has been predicted that the number of death cases due to lung cancer will increase 
[22][23]. 
1.2. Traditional methods and the importance of nano-carriers in the treatment of 
lung cancer 
Treatment of any cancer aims to remove or destroy the cancerous cells without killing normal 
cells. The most common traditional methods used for treatment include surgery, radiation, and 
chemotherapy which can be used either alone or in combination with each other [8][24]. The 
most consistent and effective option to treat patients suffering from lung cancer is surgical 
resection. In 1933, the first resection of a tumour from the lung was reported by Graham via 
pneumonectomy, and in the past two decades, this has been the principal procedure to treat lung 
cancer [25]. Stage-I lung cancer patients may be incompetent to bear surgery if their health 
condition is poor. Radiotherapy has provided relief to patients, who were incapable of 
undergoing surgery, however, the rate of cure is considerably low in comparison to surgical 
resection [26]. It is well known that radiotherapy causes damage to the surrounding cells, which 
in turn significantly leads to the loss in the functionality of the lungs. Thus, this approach may 















The most common side effects of these traditional methods are illustrated in Fig.1. Hence, there 
is an urgent need to develop newer and advanced treatment modalities that can effectively 
eliminate tumour cells which are less invasive and harmless to normal cells in comparison to 
radiotherapy and surgery. One of the new reported appro ches to cure, lung cancer is PDT 
(Photodynamic Therapy). However, this approach is used for early stage lung cancers that affect 
the central airways, especially, the light and photosensitized tissues. The therapy primarily 
employs fiber optic bronchoscope and it has been report d to be successful [28]. The concept of 
PCT (preoperative chemotherapy) came into existence as tumour cells were becoming resistant 
to anti-cancer drugs due to genetic alteration. As many as 30 clinical trials are reported on this 
study which has confirmed the feasibility of this approach with a mild expense of postoperative 
morbidity as well as mortality [29]. As chemotherapy involving anticancer drugs lacks tumour 
targeting ability, they affect the surrounding normal cells and impose rigorous side-effects in the 
patients [30].  
 
Targeted-drug delivery approaches have gained immense attention to overcome this problem 
[31]. Drug carriers can deliver drugs to the lungs, extend its duration time, regulate its 
therapeutic dose, reduce the complications and chances of the harmful effect of the toxic drug in 
the patients. This targeted approach delivers the therapeutic drug to the infected region and 
reduces its distribution to non-target tissues and organs [25]. Nanotechnology encompasses 
wide-range of nano-scale tools that can be used for therapeutic purposes. Among them, nano-
carriers have revolutionized the field of drug deliv ry [32]. These nano-carriers have been 
engineered to release and increase the duration time of drug and protect the therapeutic agent 
from early degradation and removal by phagocytic cells [33]. The respiratory system involving 
lungs are suitable for targeted drug delivery, as it provides a large surface area, which allows to 
skip the first stage metabolism and promotes the onset of rapid therapeutic action [34]. 
Development of colloidal delivery systems like micelles, liposomes and nanoparticles has 
opened a new perspective in drug delivery. Unique characteristics like small size, large surface 
area, ability to amend the surface properties are few advantages of nanoparticles which make it 
different from the other delivery systems [35]. Furthe more, the sustained release characteristics 















drug concentrations at tumor sites for longer durations [36]. The applications of different types 
of nanoparticles are discussed in Table 1.  
 
Nanoparticles facilitate a regulated release of therap utic drugs into the lung tissue, which in turn 
decreases the dosage frequency and improves the patient’s lung compliance [37]. A combination 
of intravenously injected human natural killer cells and inhaled interleukin-2 had a synergic 
effect and increased the survival rate in mice with osteosarcoma lung metastases. Furthermore, 
aerosolized delivery of liposomal interleukin-2 (IL-2) in dogs has been shown to be effective 
against pulmonary metastases from osteosarcoma [38]. Thus, nano-based delivery systems are an 
attractive approach to a therapeutic delivery agent to the lung, as it can retain the therapeutic 
agents for a longer duration in the lungs.       
2. Novel drug delivery systems for treating lung cancer  
There are different novel drug delivery systems that are developed for treating lung cancers [39] 
as illustrated in Fig. 2. Moreover, these novel drug delivery systems are further sub-divided into 
three categories as follows: 
 
2.1. Liposomes 
Liposomes consist of nano-scaled spherical vesicles which allows them to integrate hydrophobic 
and hydrophilic drugs in an aqueous centre and its ou er appearance resembles the biological 
membrane [40]. Liposomes have several unique featurs, viz; its non-toxic nature, the ability of 
its surface to get easily altered by external stimuli, physical stability, high-vascular density and 
retention time at the target site [41]. The structure of a liposome comprises of cholesterol and 
phospholipids along with an aqueous core [42]. Phosp atidylethanolamine and 
phosphatidylcholine are the most commonly used phoslipids [43]. These liposomes are 0.05-
5 µm diminutive synthetic vesicles. To obtain the desired size liposomes, one needs to follow the 
















Synthesized liposomes deliver the therapeutic agents via targeted strategies like active targeting, 
passive targeting, pH-responsive targeting, magnetic-r sponsive targeting, stimuli-responsive 
targeting, and thermo-responsive targeting. Such specific targeting improves the 
pharmacodynamic and pharmacokinetic profiles, regulates the release of therapeutic agents and 
reduces the toxicity in comparison to drug solution [45][46]. Active targeting induced by 
environment stimuli and ligands also show tremendous benefits during targeted drug delivery to 
tumor cells. Therefore, this approach increases the bioavailability of therapeutic drugs at the 
target site, decreases the toxic effects and improves the overall therapeutic response [32]. 
C-liposomes also known as conventional liposomes, are made up of cholesterol and lipids. These 
liposomes have an additional benefit as they get readily eliminated from the blood with the help 
of opsonins and reticuloendothelial system. Hence, th  results obtained by this approach 
confirmed the release of the encapsulated drug in the plasma [46].  
“Intelligent liposomes” can be used to transcend these hurdles and can be effectively used as a 
drug delivery system for treating lung cancer [47]. Another name for these liposomes is “smart 
liposomes”, consisting of a bilayer of phospholipids and surface modifiers or other covering 
molecules. These “smart liposomes” not only target th  tumor cells precisely, but also decrease 
the chances of MDR (Multi-drug resistance) [48]. The progressive liposomal preparations 
provide the potential of both mitochondrial and pH-sensitive targeting strategies to elicit the 
apoptosis and obstruct the provision of energy in resistant tumor cells [49]. A different type of 
long-circulating liposomes, also known as stealth liposomes have recently received immense 
recognition in the treatment of lung cancers. As it has more residing and circulation time, it 
enhances the drug delivery at the targeted site as well as improves the interaction between the 
therapeutic agent and the receptors in the tumor cells [50]. 
2.2. Solid lipid nanoparticles 
Solid lipid nanoparticles (SLNs) are a newly emerging surrogate to the traditional colloidal 
delivery system. SEM (scanning electron microscopy) and TEM (transmission electron 
microscopy) analysis have revealed the spherical shape of solid-lipid nanoparticles and their size, 
ranging from 50-1000 nm. The safety profile of SLNs was attributed to their biocompatible 















recommended for pulmonary drug delivery, either as suspension or dry powder, without inducing 
inflammation [52]. Solid-lipid nanoparticles contain solid lipid 0.1-30 % (w/w), which readily 
gets mixed in the aqueous solution. About 0.5–5% of sur actants are added to increase the 
stability of solid-lipid nanoparticles [53]. Solid lipid nanoparticles fall in the category of a 
nanoparticulate system containing lipids which remains solid at room temperature [54]. These 
nanoparticles have various advantages like easy modification, biocompatibility with the 
lipophilic drug, targeted delivery of the therapeutic agents, enhanced drug stability, reduced 
toxicity and in addition, avoid the first pass effect in comparison to other colloidal carries [55].  
It has been noticed that a large surface area of solid-lipid nanoparticles allows loading of a high 
amount of drug in it. Moreover, it also protects the drug from the environment and increases the 
bioavailability of drugs [56]. Of all the nano-carrier systems, Solid-lipid nanoparticles have the 
characteristics of a fat-emulsion carrier, liposomes carrier, and polymeric nanoparticles, which 
makes them the ideal carries for targeted drug delivery [57].  Generally, lipid nanoparticles are 
fabricated by natural surfactants and biocompatible l pids [55].  Most commonly used solid lipids 
for synthesizing solid-lipid nanoparticles are bee wax, cetyl alcohol, cholesterol butyrate, 
Compritol 888 ATO, Dynasan, and emulsifying wax [58]. Easy alteration of the surface of these 
nanoparticles by ligands enhances the target efficincy and makes them a valuable active-
targeted delivery system [59]. 
This approach has illustrated the inordinate potential for targeted application (especially 
intracellular), by altering gene expression and cellular signaling. Currently, fabricated ultra-solid 
lipid nanoparticles are employed to target the tumor site [60]. These nano-carriers are now used 
to enhance the bioavailability of anti-tumor drug like doxorubicin, etoposide, and idarubicin 
[61]. Additionally, solid lipid nanoparticles are also considered to be a suitable carrier for gene 
therapy [53]. 
Cationic solid-lipid nanoparticles have exhibited high transfection efficiency for targeted 
delivery of therapeutic agents to the p53 gene in lu g cancer [62]. The novel solid lipid 
nanoparticles of DCX have been prepared by using trmyristin (high-melting triglyceride). This 
method increases the concentration of DCX in tumor tissues, whereas, decreases the same in 
other organs like heart, kidney, liver, and lung. Thus, solid-lipid nanoparticles are prepared using 















2.3. Nanostructured lipid carriers 
There are few limitations of solid lipid nanoparticles like the expulsion of the drug during 
storage, the formation of crystals under the varied conditions and low payload capacity, which 
has led to the development of alternative approaches for targeted drug delivery called as 
nanostructure lipid carriers [55]. This approach is an amalgam of solid and liquid lipids, that 
exhibits reduced drug expulsion during storage and has high payload capacity [64]. These 
carriers form an occlusive layer over the surface, that reduces the water loss via trans-epidermal 
layer [65]. Different nanostructured lipid carriers have been synthesized for anticancer therapy 
[66]. 
One of them is transferrin-linked nanostructure lipid carriers, which have been formulated to 
improve gene delivery to cancer cells and also the eff ctive delivery of paclitaxel. For this, 
ligand-conjugates with transferrin are developed; then DNA and paclitaxel are loaded on 
nanostructured lipid carriers. After the loading ofnanostructured lipid carriers, ligands 
conjugated with transferrin are decorated over its surface. Moreover, the transfection efficiency 
of nanostructure lipid carriers in-vitro and in-vivo has been evaluated in the NSCLC cell line of 
humans. The results obtained revealed about high anti-tumor activity, low cytotoxicity, and high 
gene transfection capability in both in-vitro and in-vivo studies.  Hence, it can be concluded that 
the DNA and paclitaxel-loaded and transferrin-decorated nanostructured lipid carriers have 
potential to co-deliver both gene and therapeutic agents to the targeted site with high efficiency 
[67]. 
2.4. Polymer-based nano-carriers 
2.4.1. Polymeric nanoparticles 
In the field of nanotechnology, polymeric nanoparticles have emerged as an effective strategy for 
treating cancers, as their composition and morphology can be changed according to the need 
[68]. The polymer used for lung cancer treatment includes alginic acid, chitosan, gelatin, 
polycaprolactone, polylactide-co-glycolide, and polylactic acid. However, on supplementing 
these polymeric nanoparticles with sulfide bond, it regulates the release of the therapeutic drug 
[61][69]. Cationic polymers are known for its cellular toxicity and elevated aggregation in lung 















monitoring of toxicity induced by cationic polymers i  required, as on interacting with a 
biosurfactant, they trigger breathlessness.  
The biocompatible and biodegradable characteristics of these polymers result in less toxicity and 
improved bioavailability [71]. The recently developed polymeric nanoparticles have shown 
improved activity and recognition ability during the delivery of therapeutic agents. More 
recently, hyaluronan/polyethyleneimine-coated polymeric nanoparticles have been designed for 
targeted delivery of DCX (Docetaxel) to the CD4 receptor of lung tumor cells [72]. Another 
study assessed the efficacy of polylactide-tocopheryl polyethylene glycol (1000) succinate based 
nanocarrier system for the targeted delivery of CZT (Crizotinib) for treating lung cancer [73]. 
siRNA (small interfering RNA) has always remained as the challenge. Development in the field 
of nanotechnology will help in developing novel cationic polymer that can silence these siRNA 
genes in lung cancer. A study conducted in an in-vivo setting demonstrated the silencing of 50% 
targeted gene expression on the action of cationic polymers [74]. Another study highlighted the 
applicability of low-molecular-weight polymeric nanoparticles in silencing the expression of 
multiple genes of endothelial cells [75].  
2.4.2. Polymeric micelles 
For controlled release and targeted delivery of hydrophobic anti-neoplastic therapeutic agents, 
polymeric micelles are commonly used. They are considered to be potential nanocarriers, as they 
are made up of a co-polymer hydrophobic core that allows the payload of the hydrophobic 
chemotherapeutic agent and hydrophilic shell for a hydrophilic chemotherapeutic agent [76]. 
Moreover, the hydrophilic shell increases the stabili y of these polymeric nano-sized micellar 
structures. The size of the micelles can vary from 20-100nm, which is applicable for the delivery 
of hydrophobic therapeutic drugs, accommodating high payload, high drug permeability, long 
circulation time in blood stream, uniform distribution and deep tumor penetration of the drug 
[77]. With the development of personalized medicine, polymeric micelles have gained attention 
for their role in passive targeted therapy for cancer. Modifications to the surface peptides of these 
polymeric micelles improve their efficiency for precision targeting. For example, a study 
reported on integrin-associated polymeric micelles that are found to actively target the tumor 
cells [78]. The major benefit of this approach is, it  biodegradable nature for drug delivery 















It has been found that co-encapsulated polymeric mielles containing both paclitaxel and 
itraconazole significantly decreased the toxicity in NSCLC [79]. Modified polymeric micelles 
coated by α-Conotoxin ImI have emerged as a promising nanocarrier for targeted delivery of 
docetaxel to α7-nAChR gene in A549 (NSCLC) cell line [80]. 
2.4.3. Dendrimers 
Dendrimers are synthetic branched polymeric and bifurcated macromolecules, of size ranging 
from 10-100 nm. Generally, they are globular in shape and have functional groups on their 
surface which makes them excellent candidates for drug delivery [81]. Dendrimers are 
synthesized chemically with a regulated polymeric reaction involving electrostatic and 
hydrophobic interaction [82]. The surface of these nanocarriers can be fine-tuned, and 
biodegradability can also be improved [83]. These nanocarriers have emerged as a useful tool in 
cancer therapy because of its symmetrical shape, biocompatibility, easy biodegradability, high 
payload, and multiple conjugation point that aid in surface modification [84]. 
The potential of this nanocarrier has been well-repo ted in the literature [85]. Effective 
adsorption of peptide conjugated dendrimers has been r ported in an athymic mouse model 
bearing lung cancer that revealed the real potential of this nanocarrier system in treating lung 
cancer [86]. Moreover, PEGylated dendrimers exhibited promising applications when used as an 
aerosol-inhaled drug delivery model [87]. Substantial improvement has also been recorded for 
doxorubicin delivery via dendrimers.   
2.5. Inorganic nanoparticles 
2.5.1. Magnetic nanoparticles  
This type of nanoparticles gets affected by surrounding magnetic fields and reach the target site 
in the body either by an active or passive strategy, because of their ligands. The FDA has 
approved the usage of magnetic nanoparticles along with chemotherapy, which is a giant leap in 
treating cancers [88]. 
Magnetic nanoparticles are made up of super paramagnetic material of size >25 nm. These 
nanoparticles are either biodegradable or non-biodegradable [89]. Non-biodegradable magnetic 















and facilitates its excretion through the kidneys [90]. When an external magnetic field is applied 
to these magnetic nanoparticles, they exhibit thermic effects which trigger cellular apoptosis 
above 42°C and direct killing at 45°C [91]. 
Magnetic nanoparticles comprise a magnetic core which is surrounded by a functional coat. The 
magnetic core is made up of materials like cobalt, gold, iron, and nickel which provide the 
magnetic properties to the core. On the other hand, the surface coat prevents agglomeration and 
reduces the interaction of the magnetic core with other particles [92]. This surface/functional 
coat can either be a ligand or a biologically active therapeutic substance. Nickel is a trace 
element, which is essential for humans but in excessiv  amounts induces toxicity in the 
gastrointestinal and pulmonary systems [93]. Because of the biocompatibility of Fe3O4, 
nanoparticles conjugated with iron oxide are most widely used for the treatment of lung cancer. 
In addition, nanoparticles of Fe2O3 are also used for cancer therapy [94]. The advantages nd 
disadvantages of magnetic particles are shown in Table 2. A study showed the enhanced 
cytotoxicity activity of doxorubicin-magnetic nanoparticles because of the paramagnetic nature 
of doxorubicin and magnetic nature of iron oxide [95]. 
Magnetic nanoparticles of iron oxide coated with gold conjugated with 225-antibody have been 
designed to target EGFR (epithelial-growth factor receptor). These nanoparticles have shown 
DNA damage and cell-cycle revocation in M/G2-phase [103]. Another study reported the 
toxicity induced by C225-nanoparticles in Non-small-ce l lung carcinoma (NSCLC) [104]. It is 
well known that nanoparticles of smaller sizes get inhaled and get aggregated in the lungs [105]. 
In order to overcome this problem, nowadays, magnetic nanoparticles are entrapped in micro-
sized particles. D-mannitol and iron-oxide nanoparticles are most commonly used to synthesize 
magnetic nanocomposite nano-sized particles. This appro ch prevents the spreading of the 
therapeutic agents in blood and delivers the drug directly to the target site [106]. 
Cisplatin, being a hydrophobic drug, needs a special carrier to improve its antitumor activity. 
Therefore, a functionalized nanoparticle of Fe3O4 associated with PEG-PLGA copolymer has 
been developed which shows the improved antitumor activity of cisplatin in lung cancer [96]. It 
has been found that Iron-oxide nanoparticles conjugated with gold improves the bio-availability 















nature of gold, gadolinium, and platinum at the tumor site, nanoparticles of these elements are 
also used for radiotherapy as well as other diagnostic purposes [107]. 
2.6. Carbon nanotubes 
Carbon nanotubes are hydrophobic-tubular structures made up of carbon atom between 4 nm to 
100 mm diameter and can vary according to the arrangement of graphene molecules [108]. 
Intrinsically, these carbon nanotubes are insoluble in any organic solvents or aqueous solutions 
and toxicity induced by these in a biological fluid is a major challenge that needs to be addressed 
[109]. Chemical modification improves the biocompatibili y, reduces toxicity and transforms 
them into water-soluble nano-carriers [110]. Carbon na otubes have a large surface area. The 
graphene cavity of carbon nanotubes can accommodate high payloads and has distinct 
mechanical, electron emission and optical properties which make them a candidate of interest. 
This nanocarrier has high penetration power as it mimics the structure of a fine needle and the 
functionalized surface is an additional advantage which improves tumor targeting [111].     
  
Cisplatin was the first anti-tumor drug which was conjugated with single-walled carbon 
nanotubes for targeting the receptors of epidermal growth factor. The results obtained, revealed 
an improved efficacy against squamous cancer cells that were showing elevated expression of 
EGFR. In addition, these showed an enhanced activity against head and neck tumor, as compared 
to passive targeting because of its nano size [112]. Moreover, carbon nanotubes contain several 
functional sites on their surface, which enable scientists to perform multiple functions with a 
single nanocarrier [113]. In-vitro and preclinical trials on murine S180 and PC3 celllines of 
docetaxel loaded carbon nanotubes have shown effective results in comparison to free docetaxel 
[114]. 
Pluronic F127, the non-ionic surfactant has been used to stabilize supramolecular complexes of 
carbon nanotubes containing doxorubicin. The drug payload capacity was determined by 
fluorescence spectrophotometry in multi-walled carbon nanotubes. The intensity of doxorubicin 
fluorescence majorly depends on the concentration of carbon nanotubes [115]. Furthermore, an 
efficient releasing of carbon nanotubes can be assured through transmission micrograph. 















pluronic complexes and plain doxorubicin [116]. Currently, there are various formulations of 
carbon nanotubes that have been developed with potential outcomes. 
2.7. Quantum dots 
Lately, nanofabrication has enabled researchers to ynthesize nano-sized colloidal particles 
possessing atom-like properties, known as quantum dots (QDs) [117]. These QDs are considered 
to be a novel approach for treating lung cancers. A the surface modification of these 
nanoparticles enhance the biocompatibility and solubility, which makes it a superior fluorescent 
probe in comparison to organic fluorophores [118]. Large absorption spectra, high photo 
bleaching, and photo stability are few peculiar characteristics of these QDs [119]. QDs show 
redundant cycles of fluorescence and excitation with a narrow range of emission spectra [120]. 
Generally, QDs comprise the elements of group II-VI/ II-V. Groups II-IV includes elements like 
cadmium–telluride, cadmium–selenide, zinc–selenide, and zinc sulfide. Whereas, groups III-V 
include the elements like gallium arsenide, gallium nitride, indium arsenide and indium 
phosphide [121]. 
QDs contain a core and a ‘cap’ or ‘shell’ along with a coating of polymer as shown in Fig.3. The 
cap of the QDs guards the core which is made up of metal complexes. Moreover, lipid-coated-
QDs showed promising results towards cancerous cell[122]. Thus, QDs are significantly used 
for biomedical imaging, and for targeting and labelling of biological entities. During in-vivo 
studies, QDs coated with PEG were not recognized by the reticuloendothelial system increasing 
their circulation time within the biological system [123]. QDs are also used for biological 
imaging, cellular and molecular tracing, estimating toxicity profile, in-vitro imaging 
(multiplexed), molecular labelling as markers, signal transduction and immuno-histochemical 
detection [124]. The aqueous solubility of QDs can be increased by coating them with polymer 
and ligand exchange [71][125]. Due to the immense applications of QDs for diagnostic and 
imaging, now they are also being used for therapeutic benefits. 
3. Pre-clinical and clinical studies 
Presently, there are several nanoparticle based therapeutic approaches that are under pre-clinical 
and clinical trials waiting for the approval by the FDA (Food and Drug Administration of USA) 
or EMA (European Medicines Agency of Europe) [126]. Various nanoparticle based 















Liposomal based nanocarriers encapsulating Doxil (an anti-tumour drug), sold under the name 
“Abraxane” was the first FDA approved cancer nano-medicine. Several nano-medicines viz; 
DaunoXome, Marqibo and Myocet were later approved [127]. The DOTAP/ Chol TUSC2 (lipid-
based nanoparticles) formulation is under phase I clinical trial which is being studied for treating 
metastatic lung cancer patients. SLNs is a different class of carrier for targeted drug delivery. 
The formulation, SLN-carrier p53 was compared with Lipofectin (commercially available drug), 
in which SLN-carrier p53 was found to be effective and efficient in treating the transfected p53-
null H1299 lung cancer cells. This study highlights the potential of this approach and motivates 
for a preclinical and clinical assessment for its usage in chemo/gene therapy as well as in 
molecular imaging of cancers [62]. Moreover, one of the polymeric nanoformulations “Genexol-
PM” is being currently assessed for phase II clinical trials in NSCLC patients [128]. With the 
success of different formulation of NDDS in the commercial and clinical realm, substantial 
efforts are being taken to exploit the available approved nanomedicines for their therapeutic 
potential. We have summarised the current studies related to clinical trials on nanoparticle based 
formulations for lung cancer in Table 3. 
 
4. Future prospects 
Novel drug delivery systems (NDDS) are developed with a diverse range of applications and 
have shown promising results in treating diseases with more safety, efficacy and precision. Many 
of the clinical approaches involving NDDS not only regulates the indented pattern of drug level 
within the blood, but also aids in targeting the drugs to a specific site or site of action. As a 
result, it circumvents the dose-associated toxicity and side effects. Despite the various 
applications and benefits, nanotechnology cannot be termed as flawless. As we are moving from 
microparticles to nanoparticles; the size decreases nd the number of particles as well as the 
surface area increases. The increased surface area of the nanoparticles results in an augmented 
chemical reactivity leading to an uncertainty as to how these particles will react under different 
conditions. The increased chemical reactivity of nanoparticles brings about the production of 
reactive oxygen species (ROS), which may cause oxidative stress, inflammation, and damage to 
DNA, proteins and membranes, ultimately leading to toxicity. In the future, nano-toxicological 















nanoparticle-based drug delivery system is predicte to overgrow and unlock a new dimension 
for treating lung cancer. It is believed that extensive research in this field will endeavour new 
paradigms and replace the traditional dosage approach with NDDS, which will improve the 
health care delivery system in the near future. 
4. Conclusion 
Nanotechnology beholds infinite potential and innovative applications which are being 
continuously explored for detecting, diagnosing, imaging and treating different types of cancers. 
Development in this field has already aided in resolving the issues of traditional medical 
interventions like non-specific targeting, low therapeutic efficiency, unforeseen side-effects, and 
drug-resistance. These nanoparticles-based drug delivery systems have become the ideal carrier 
for cancer treatment as they can be easily modified. Various nano-carriers like liposomes, solid-
lipid nanoparticles, nanostructured lipid carriers, polymeric nanoparticles, polymeric micelles, 
dendrimers, magnetic nanoparticles, carbon nanotubes, and quantum dots have been developed 
and used in combination with different medical interventions for tracking and targeting the 
infected site as well as deliver the therapeutic agents. Nanoparticles with multiple structures 
allow alteration of surface for delivering water-insoluble drugs and impart them the ability to 
surpass the biological barriers and target desired sit  within the body. This therapeutic approach 
has developed hope among the patients suffering from cancer and received an overwhelming 
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Table 1. Applications of different types of nanoparticles [25] 
 
Types of nanoparticles  Application of nanoparticles 
DD GT IM MRI PDT PTT 
Carbon Nanotubes √ √   √  
Dendrimers   √    
Gold Nanoparticles √ √   √ √ 
Liposomes √  √    
Magnetic Nanoparticles √   √   
Polymeric micelles √  √    
Quantum dots √  √    
DD- Drug Delivery; GT- Gene therapy; IM- Imaging; MRI- Magnetic Resonance Imaging; PDT- 
Photodynamic Therapy; PPT- Photothermal Therapy 
 
 
Table 2. Advantages and disadvantages of different types of magnetic nanoparticles 
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• Induce apoptosis in 
the targeted area 
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tumor site and 
enhance x-ray 
effect 
• Cause toxicity 




















• Prevent systemic 
targeting as drug 
deposits in lungs 
drug in upper 
respiratory tract 
• Less availability 
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Table 3. List of clinical trials on nanoparticle based formulations for lung cancers 
Drug Carrier Development 
stage 
Objectives of study Reference 
Liposomal SN-38 Liposomes Phase -II To stop the growth of tumor 
cells, either by killing the 





Liposomes Phase -II To determine the dose of 
Irinotecan injection 
To study the efficacy of 








Nanoparticles Phase-II To study the effect of 
docetaxel nanoparticle 
injection in patients with 
squamous cell non-small cell 
lung cancer (NSCLC) who 
have progressed after 









Nanoparticles  Phase-II To study the combination 
effect of paclitaxel albumin-
stabilized nanoparticle 
formulation along with 





Nanoparticles Phase-I To find the highest dose of 
DOTAP:Chol-TUSC2 that 
can be safely given in 
combination with Tarceva 
(erlotinib hydrochloride) to 





















 To compare the efficacy of 
Paclitaxel and Cisplatin 
versus Paclitaxel loaded 
polymeric micelles and 
Cisplatin in advanced non 

















Fig. 1. General diagrammatic representation of side-effects associated with traditional 
approaches 
 
Fig. 2. Systematic representation of different novel drug delivery system i.e. (a) 
Nanostructured lipid carrier (b) Solid lipid nanoparticles (c) Liposomes (d) Lipid micelle 
(e) Nanostructured lipid emulsion (f) dendrimers (g) Carbon nanotube (h) Iron oxide 





























• Lung cancer is one of the most prevalent form of cancer worldwide. 
• Traditional treatment methods includes surgery, radiation and chemotherapy. 
• Main side effects of existing treatments are nonspecific targeting and toxicity. 
• Novel drug delivery offers improved bioavailability and site-specific targeting. 
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